Language selection

Search

Patent 2298762 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 2298762
(54) English Title: THERAPEUTIC COMPOSITIONS CONSISTING OF CLARIFIED MULTI-FILTERED SOLUABLE SODIUM SILICATE IN LIQUID FORM ARE FOUND TO MODIFY SUPPRESSOR CELLS AND ENHANSE THE HUMAN IMMUNE SYSTEM TOPREVENT RECURRENCE OF HERPES INFECTIONS
(54) French Title: COMPOSITIONS THERAPEUTIQUES CONSISTANT EN DU SILICATE DE SODIUM SOLUBLE MULTI-FILTRE CLARIFIE SOUS FORME LIQUIDE CAPABLES DE MODIFIER LES CELLULES SUPPRESSEURS ET DE STIMULER LE SYSTEME IMMUNITAIRE HUMAIN AFIN DE PREVENIR LA RECURRENCE DES INFECTIONS A HERPES
Status: Expired and beyond the Period of Reversal
Bibliographic Data
Abstracts

English Abstract


This discovery and invention relates to a therapeutic
composition of matter which may be used for the home
treatment of herpes-caused cutaneous infections whereby
the formation of new lesions is prevented. The preferred
composition comprises a liquid which is a clarified,
multi-filtered soluble sodium silicate in which the minerals are
suspended in an aqueous solution. Application to the
infection is found to modify the suppressor cells and such
enhanses the immune system. This new therapy is a
remarkable improvement to the present art for treatment
of Herpes viruses as the disease symptoms disappear
permanently while existing treatments only reduce the
severity of the disease. Up to this time there has not been
an established, efficient practical product or method to
permanently prevent the recurrence of Herpes lesions.


Claims

Note: Claims are shown in the official language in which they were submitted.


CLAIMS
The embodiments of the invention in which an
exclusive property or privilege is claimed are
defined as follows:
CLAIM 1. A therapeutic composition of
matter, consisting of an aqueous sodium silicate
solution, may be utilized for the treatment of
Herpes infections thereby blocking the virus
and preventing new lesion formation.

Description

Note: Descriptions are shown in the official language in which they were submitted.


CA 02298762 2000-02-11
SPECIFICATION
This invention relates to the field of medical
therapeutics and specifically that class which deals
with lesions of the skin caused by Herpes viruses.
Processes previously known and used included
many topical analgesics which were not singularly
effective. While some tablets based on Acyclovir
reduced the severity of the disease, they require
lifetime use and do not result in permanent
l, elimination of lesions.
This invention provides a patient administered
substance which overcomes the previous
shortcomings and is simple to apply. It promotes
improved healing time with no scarring of the skin
15 and reduces the opportunity for entry of other
infective agents. Additionally it has no side effects,
is not carcinogenic to humans and is rated GRAS
(generally regarded as safe) by the Food and Drug
Administration. A major advantage to be attained
will be the low cost of distribution as the substance
is already in bulk supply at a few cents per ounce.
The background of the disease is outlined to afford
a better understanding of the nature of the
invention. A cure has escaped the best medical
z5 research efforts for the last twenty years. The
family of Herpes viruses has been affecting animals
for many years but reached epidemic proportions
in Humans in the early 1980's. There are five
major types infecting humans and demonstrate six
so stages of infection from prodrome to replacement
of the scabs by new cells. It is estimated , as Herpes
-2-

CA 02298762 2000-02-11
is not a reportable disease, that some 60 million
Americans are infected with the disease and one
hundred thousand new cases develop annually.
Some estimates suggest that 50 % of the world
s population is affected with some of the under-
developed countries reporting much higher figures.
I have a number of documented reports that a
single treatment with aqueous sodium silicate
eliminates the recurrence of Herpes lesions. In
to several cases where an immunodeficiency was
present , it required additional treatment where a
second but much smaller lesion appeared.
Normally, the immune system requires about seven
days to produce an adequate level of antibodies. By
15 that time it is too late as the viruses have invaded
skin cells and through parasitic action have utilized
cell DNA to reproduce and cause highly infective
lesions. The basic substance discovered to cure
herpes infections is a liquid formation, being a
soluble sodium silicate, available from National
Zo
Silicates Ltd. of Toronto, Ontario and fully
described in their Bulletin 17-1.
The substance has been used in commercial
applications for over 100 years. The only medical
25 use todate is to control bacteria in eggs and
washing meat products. Its use as a cure for
Herpes is a new discovery and superior to
substances previously used in the medical
profession.
so Experimentation which lead to the
discovery was as follows;
Mid-1980's testing on Human volunteers showed
no recurrence of the symptoms of Herpes ,neither
-3-

CA 02298762 2000-12-27
has there been any recurrence in these cases after
15 years.
In-vitro testing was done by USA 's N.I.H. of
Bethesda , Maryland, USA under a secrecy
agreement. This was carried out at the University
of Birmingham , USA and showed some
suseptability but clearly demonstrated that the
presence of the immune system is essential . Upon
search of the Canadian patent database, no patents
were found matching my query utilizing "Herpes
viruses" and ' sodium silicate" A similar search of
the US. Patent and TM office showed no
matching of the query. A second Canadian search
utilizing "Herpes and " Infection " was matched in
15 57 out of 1,419.762 patents. In study of these 57
patents, there was no reference to
sodium silicate.
Search of a specific patent (USA) (Birchall) , (#
5,814,347 ) which claims lithium silicate as a
zc treatment for Herpes infections. It mixes several
substances such as carbonates, talc , silica and
sodium silicate and utilizes them as drying agents.
This, in my opinion, does not conflict with my
discovery which teaches that a single, liquid
z5 solution of sodium silicate applied to the infections
moderates the immune system in such a way to
prevent the recurrence of lesions..permanently.
~~F-

CA 02298762 2000-02-11
DRAWINGS
Since the invention is not suitable for proper
description by drawings, included are copies of
illustrations of 1. The structure and life cycle
of the virus , and 11. The natural process of the
human immune ststem. The explanation as to
why the discovered substance effectively
prevents the recurrence of lesions is not well
understood at this time and extensive
to additional research will have to be carried out
to confirm reasons. However, from results from
human tests, there can be no explanation
other than that the immune system has been
enhanced to maintain an adequate level of
15 antibodies to maintain the dormant viruses
inactive. Additionally, the mechanical features
of the substance may coat skin cells and
prevent escape of viruses from infected cells.
_5_

Representative Drawing

Sorry, the representative drawing for patent document number 2298762 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Time Limit for Reversal Expired 2013-02-11
Inactive: Adhoc Request Documented 2012-11-15
Letter Sent 2012-02-13
Inactive: Office letter 2008-05-02
Inactive: Reversal of will be deemed expired status 2008-05-02
Inactive: Adhoc Request Documented 2008-03-11
Inactive: Payment - Insufficient fee 2008-03-07
Letter Sent 2008-02-11
Inactive: Office letter 2006-12-13
Inactive: Office letter 2005-03-11
Amendment Received - Voluntary Amendment 2003-10-01
Grant by Issuance 2001-06-12
Inactive: Cover page published 2001-06-11
Pre-grant 2001-03-19
Small Entity Declaration Determined Compliant 2001-03-19
Inactive: Final fee received 2001-03-19
Notice of Allowance is Issued 2001-03-05
Inactive: Correspondence - Prosecution 2001-03-05
Letter Sent 2001-03-05
Notice of Allowance is Issued 2001-03-05
Inactive: Approved for allowance (AFA) 2001-02-08
Amendment Received - Voluntary Amendment 2000-12-27
Inactive: S.30(2) Rules - Examiner requisition 2000-12-11
Application Published (Open to Public Inspection) 2000-12-02
Inactive: Cover page published 2000-12-01
Letter sent 2000-10-03
Advanced Examination Determined Compliant - paragraph 84(1)(a) of the Patent Rules 2000-10-03
Early Laid Open Requested 2000-09-27
Inactive: Correspondence - Prosecution 2000-09-27
Letter Sent 2000-09-06
Request for Examination Received 2000-08-11
Request for Examination Requirements Determined Compliant 2000-08-11
All Requirements for Examination Determined Compliant 2000-08-11
Inactive: Office letter 2000-07-25
Inactive: Correspondence - Formalities 2000-07-07
Inactive: Advanced examination (SO) fee processed 2000-07-07
Inactive: Advanced examination (SO) 2000-07-07
Inactive: Correspondence - Formalities 2000-05-08
Inactive: Correspondence - Formalities 2000-05-01
Inactive: IPC assigned 2000-03-28
Inactive: IPC assigned 2000-03-28
Inactive: First IPC assigned 2000-03-28
Inactive: IPC assigned 2000-03-28
Inactive: Filing certificate - No RFE (English) 2000-03-14
Application Received - Regular National 2000-03-13

Abandonment History

There is no abandonment history.

Fee History

Fee Type Anniversary Year Due Date Paid Date
Application fee - small 2000-02-11
Advanced Examination 2000-07-07
Request for examination - small 2000-08-11
Final fee - small 2001-03-19
MF (patent, 2nd anniv.) - small 2002-02-11 2001-11-29
MF (patent, 3rd anniv.) - small 2003-02-11 2003-02-11
MF (patent, 4th anniv.) - small 2004-02-11 2003-12-31
MF (patent, 5th anniv.) - small 2005-02-11 2005-02-01
MF (patent, 7th anniv.) - small 2007-02-12 2005-02-14
MF (patent, 6th anniv.) - small 2006-02-13 2006-02-01
MF (patent, 8th anniv.) - small 2008-02-11 2008-02-10
MF (patent, 9th anniv.) - small 2009-02-11 2009-02-09
MF (patent, 10th anniv.) - small 2010-02-11 2010-02-11
MF (patent, 11th anniv.) - small 2011-02-11 2010-02-19
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
PAUL M. PIDCOCK
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Claims 2000-02-10 2 45
Drawings 2000-02-10 2 179
Abstract 2000-02-10 1 28
Description 2000-02-10 4 166
Description 2000-12-26 4 155
Claims 2000-12-26 1 13
Drawings 2000-07-23 2 90
Filing Certificate (English) 2000-03-13 1 163
Acknowledgement of Request for Examination 2000-09-05 1 178
Commissioner's Notice - Application Found Allowable 2001-03-04 1 164
Notice: Maintenance Fee Reminder 2001-11-13 1 121
Notice: Maintenance Fee Reminder 2002-11-12 1 118
Notice: Maintenance Fee Reminder 2003-11-12 1 114
Notice: Maintenance Fee Reminder 2004-11-14 1 119
Notice: Maintenance Fee Reminder 2005-11-14 1 118
Notice: Maintenance Fee Reminder 2006-11-14 1 120
Notice: Maintenance Fee Reminder 2007-11-13 1 122
Notice of Insufficient fee payment (English) 2008-03-06 1 93
Notice: Maintenance Fee Reminder 2008-11-12 1 130
Notice: Maintenance Fee Reminder 2009-11-15 1 120
Notice: Maintenance Fee Reminder 2011-11-14 1 121
Maintenance Fee Notice 2012-03-25 1 172
Second Notice: Maintenance Fee Reminder 2012-08-13 1 118
Notice: Maintenance Fee Reminder 2012-11-13 1 119
Fees 2003-02-10 1 156
Correspondence 2000-03-13 1 12
Correspondence 2000-05-08 5 247
Correspondence 2000-04-30 3 165
Correspondence 2000-09-26 2 98
Fees 2003-12-30 2 82
Fees 2001-11-28 1 71
Correspondence 2000-07-06 4 119
Correspondence 2000-07-06 4 214
Correspondence 2000-07-24 1 11
Correspondence 2001-03-18 2 107
Fees 2004-12-05 1 69
Correspondence 2005-03-10 1 14
Fees 2005-02-13 1 93
Fees 2006-01-31 1 117
Correspondence 2006-12-12 1 11
Correspondence 2006-12-10 2 36
Fees 2008-02-10 2 100
Correspondence 2008-05-01 1 13
Fees 2009-02-08 2 391
Fees 2010-02-10 2 147
Fees 2010-02-18 1 22